From the Journals

Longer withdrawal time reduces miss rates in screening colonoscopy


 

FROM THE AMERICAN JOURNAL OF GASTROENTEROLOGY

During screening colonoscopy, a scope withdrawal time (WT) of 9 minutes versus 6 minutes led to a reduced adenoma miss rate (AMR) and advanced adenoma miss rate (AAMR) and an improved adenoma detection rate (ADR), according to a randomized controlled trial conducted in China.

“Individual colonoscopists may acquire significant benefits in the ADR, AMR, AAMR, and high-risk adenoma miss rate from a 3-minute WT prolongation without compromising detection efficiency,” Zhao-Shen Li, MD, PhD, director, department of gastroenterology, Changhai Hospital and Second Military Medical University, Shanghai, said in an interview.

Based on evidence to date, the 9-minute WT “deserves to be considered as a new quality indicator to further optimize colonoscopy quality,” Dr. Li added.

The study is published online in the American Journal of Gastroenterology.

Dr. Ziad F. Gellad, Duke University, Durham, N.C.,

Dr. Ziad F. Gellad

“This study certainly supports the notion that lengthening the examination time during colonoscopy results in more adenomas being detected,” Ziad F. Gellad, MD, who wasn’t involved in the study, told this news organization.

“When linking that with other studies showing a positive correlation between adenoma detection rate and interval cancers, we can conjecture that these longer exams will result in improved cancer detection. This makes intuitive sense,” said Dr. Gellad, associate professor of medicine, Duke University Medical Center, Durham, N.C.

In an earlier study, Dr. Li and colleagues found that prolonging the WT from a mean of 6 minutes to 9 minutes significantly improved the ADR (27.1% vs. 36.6%, P = .001).

Their latest study involved 733 asymptomatic adults aged 40-75 years undergoing screening colonoscopy by 15 gastroenterologists at 11 tertiary hospitals in China.

Participants were randomly allocated to segmental tandem screening colonoscopy with 9-minute withdrawal first (9MF) followed by 6-minute withdrawal (6MF) or vice versa.

In an intention-to-treat analysis, compared with 6MF, 9MF significantly reduced the lesion-level AMR (14.5% vs. 36.6%, P < .001), which was the primary outcome, and the participant-level AMR (10.9% vs. 25.9%; P < .001).

The 9MF also significantly reduced the AAMR (5.3% vs. 46.9%, P = .002), multiple AMR (20.7% vs. 56.5%; P = .01), and high-risk AMR (14.6% vs. 39.5%; P = .01) – without compromising detection efficiency.

The longer withdrawal time was also associated with a lower false-negative rate for adenomas (5.2% vs. 11.7%; P = .002) and high-risk adenomas (2.2% vs. 5%; P < .05), as well as a lower rate of shortening the surveillance schedule (P < .001).

A 9-minute mean WT also led to an improved ADR (42.3% vs. 33.5%, P = .02). The ADR improvement was associated with diminutive (P = .01), flat (P = .01), and tubular adenomas (P = .02).

Notably, colonoscopists with high ADRs (≥ 25%) in routine practice also showed a tendency of ADR improvement through a 3-minute prolongation (41% vs. 34.8%; P for interaction = .62), the investigators wrote.

Dr. Gellad said in an interview the study “reinforces the importance of careful inspection of the colonic mucosa during colonoscopy withdrawal. This should take as long as it takes to do it right, and that will vary by patient and by endoscopist.”

“Measurement of withdrawal time is helpful for quality improvement purposes when physician detection rates or miss rates are below goal,” Dr. Gellad added, “but timing the withdrawal should not be a goal in and of itself,”

The study was supported by the National Science and Technology Plan Project of the Ministry of Science and Technology of China. The authors reported no relevant financial relationships. Dr. Gellad is a consultant for Merck and Novo Nordisk and a cofounder of Higgs Boson.

A version of this article first appeared on Medscape.com.

Recommended Reading

‘Unappreciated’ ties between COVID and gut dysbiosis
MDedge Internal Medicine
FDA rejects bulevirtide for hepatitis D
MDedge Internal Medicine
Patients at risk for Barrett’s esophagus rarely screened
MDedge Internal Medicine
FDA expands tenofovir alafenamide (Vemlidy) use to adolescents with chronic HBV
MDedge Internal Medicine
Noninvasive tests may provide prognostic value in NAFLD
MDedge Internal Medicine
Novel drug eases Parkinson’s-related constipation in early trial
MDedge Internal Medicine
Resmetirom reduces liver, CV risk factors in NASH with cirrhosis
MDedge Internal Medicine
NAFLD patients with diabetes have higher fibrosis progression rate
MDedge Internal Medicine
World falls short on HBV, HCV elimination targets
MDedge Internal Medicine
Downward trend in Medicare payments for GI services
MDedge Internal Medicine